



Predicting Psychopathological Onset: Early Signs of Neuropsychiatric Diseases

Guest Editor:

Dr. Marco Costanzi

Department of Human Sciences,
Lumsa University, 00100 Rome,
Italy

Deadline for manuscript
submissions:

closed (10 December 2021)

Message from the Guest Editor

Dear Colleagues,


Millions of people worldwide are affected by neuropsychiatric disorders, such as anxiety, major depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder, and post-traumatic stress disorder. Although clinical tools are valuable in treating psychopathologies, the identification of early signs of psychopathology remains a main target to be reached in order to improve treatment effectiveness and reduce poor outcomes.

The assessment of biological, behavioural, and cognitive markers of psychopathology could provide a significant support in pre-clinical phases to identify vulnerability factors, understand the course of illness and predict its outcome, as well as aid clinicians in the therapeutic decision-making process.

In this Special Issue of the *Journal of Personalized Medicine*, papers addressing early markers of psychopathology aimed at improving diagnostic tools and at envisaging personalized therapies are welcome.

Prof. Marco Costanzi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)